Treatment of homozygous familial hypercholesterolaemia in paediatric patients: A monocentric experience

Abstract

Background

Homozygous familial hypercholesterolaemia is a rare life-threatening disease characterized by markedly elevated low-density lipoprotein cholesterol (LDL-C) concentrations and accelerated atherosclerosis. The presence of double gene defects in the LDL-Receptor, either the same defect (homozygous) or two different LDL-raising mutations (compound heterozygotes) or other variants, identify the homozygous phenotype (HopFH). Apheresis is a procedure in which plasma is separated from red blood cells before the physical removal of LDL-C or the LDL-C is directly removed from whole blood. It is currently the treatment of choice for patients with HopFH whose LDL-C levels are not able to be reduced to target levels with conventional lipid-lowering drug therapy.

Design

The aim of this study is to report a cohort of six paediatric patients and to evaluate the long term efficacy of combined medical therapy and LDL-apheresis on LDL-C reduction.

Methods

We collected data from six children with confirmed diagnosis of HopFH (two females and four males; age range at diagnosis 3–8 years, mean 6 ± 1 years) from a single clinical hospital in Italy from 2007 to 2017.

Results

Clinical manifestations and outcomes may greatly vary in children with HopFH. Medical therapy and LDL-apheresis for the severe form should be started promptly in order to prevent cardiovascular disease.

Conclusions

Lipoprotein apheresis is a very important tool in managing patients with HopFH at high risk of cardiovascular disease. Based on our experience and the literature data, the method is feasible in very young children, efficient regarding biological results and cardiac events, and safe with minor side-effects and technical problems. We advise treating homozygous and compound heterozygous children as soon as possible.

Keywords

Homozygous familial hypercholesterolaemia LDL-apheresis cardiovascular risk

Get full access to this article

View all access options for this article.

References

Siri-Tarino

Krauss

. The early years of lipoprotein research: From discovery to clinical application. J Lipid Res 2016; 57: 1771–1777.

Wiegman

Gidding

Watts

et al.

Familial hypercholesterolaemia in children and adolescents: Gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36: 2425–2437.

Sjouke

Kusters

Kindt

et al.

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: Prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015; 36: 560–565.

Catapano

Graham

De Backer

et al.

2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37: 2999–3058.

Piepoli

Hoes

Agewall

. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2016; 23(11): NP1–NP96.

Fahed

Shibbani

Andary

et al.

Premature valvular heart disease in homozygous familial hypercholesterolemia. Cholesterol 2017; 2017: 3685265–3685265.

Ross

. Statins in the management of pediatric dyslipidemia. J Pediatr Nurs 2016; 31: 723–735.

Vuorio

Kuoppala

Kovanen

et al.

Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2017; 7: CD006401–CD006401.

Hovingh

Goldberg

Moriarty

. Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit. J Clin Lipidol 2017; 11: 602–616.

10.

Cuchel

Bruckert

Ginsberg

et al.

Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35: 2146–2157.

11.

France

. Homozygous familial hypercholesterolaemia: Update on management. Paediatr Int Child Health 2016; 36: 243–247.

12.

Reiner

. Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol 2015; 12: 565–575.

13.

II Italian Consensus Conference on LDL-apheresis, Rome, Italy, 15 May 2009. http://www.sisa.it/upload/II_CCI_LDL_aferesi.pdf (accessed May 2018).

14.

Nakaji

Yamamoto

. Membranes for therapeutic apheresis. Ther Apher 2002; 6: 267–270.

15.

Zech

Jr Hoeg

. Correlating corneal arcus with atherosclerosis in familial hypercholesterolemia. Lipids Health Dis 2008; 10: 7–7.

16.

Winder

. Relationship between corneal arcus and hyperlipidaemia is clarified by studies in familial hypercholesterolaemia. Br J Ophthalmol 1983; 67: 789–794.

17.

Macchiaiolo

Buonuomo

Valente

et al.

Corneal arcus as first sign of familial hypercholesterolemia. J Pediatr 2014; 164: 670–670.

18.

Hickey

Maurer

Mulcahy

. Arcus senilis: Its relation to certain attributes and risk factors in patients with coronary heart disease. Br Heart J 1970; 32: 449–452.

19.

Winder

. Relationship between corneal arcus and hyperlipidaemia is clarified by studies in familial hypercholesterolaemia. Br J Ophthalmol 1983; 67: 789–794.

20.

Reiner

. Impact of early evidence of atherosclerotic changes on early treatment in children with familial hypercholesterolemia. Circ Res 2014; 114: 233–235.

21.

Von Dryander

Fischer

Passauer

et al.

Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. Atheroscler Suppl 2013; 14: 39e44–39e44.

22.

Wang

Richhariya

Gandra

et al.

Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. J Am Heart Assoc 2016; 5: e003294–e003294.

23.

Harada-Shiba

Arai

Oikawa

et al.

Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb 2012; 19: 1043–10604.

24.

Stefanutti

Di Giacomo

Vivenzio

et al.

Low density lipoprotein apheresis in a patient aged 3.5 years. Acta Paediatr 2001; 90: 694–701.

25.

Civeira

. International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173: 55–68.

26.

Lefort

Saheb

Bruckert

et al.

Impact of LDL-apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia. Atherosclerosis 2015; 239: 158e162–158e162.

27.

Palcoux

J-B

Atassi-Dumont

Lefevre

et al.

Low-density lipoprotein apheresis in children with familial hypercholesterolemia: Follow-up to 21 years. Ther Apher Dial 2008; 12: 195–201.

28.

Dann

Shamir

Mashiach

et al.

Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis. Transfus Apher Sci 2013; 49: 268e277–268e277.

29.

Rallidis

Naoumova

Thompson

et al.

Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart 1998; 80: 583–590.

30.

Beigel

. Homozygous familial hypercholesterolemia: Long term clinical course and plasma exchange therapy for two individual patients and review of the literature. J Clin Apher 2009; 24: 219–224.

31.

Hudgins

Kleinman

Scheuer

et al.

Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Cardiology 2008; 102: 1199–1204.

32.

Stefanutti

Julius

Watts

et al.

Toward an international consensus – integrating lipoprotein apheresis and new lipid-lowering drugs. J Clin Lipidol 2017; 11: 858–871.